CytomX Therapeutics Inc (NASDAQ:CTMX) has received an average recommendation of “Hold” from the seven research firms that are covering the stock. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $28.00.
CTMX has been the subject of a number of research reports. Zacks Investment Research cut shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, February 14th. Oppenheimer Holdings Inc. reiterated a “market perform” rating on shares of CytomX Therapeutics in a report on Tuesday, January 3rd. Nomura began coverage on shares of CytomX Therapeutics in a report on Wednesday, March 1st. They issued a “buy” rating on the stock. Cowen and Company reiterated a “buy” rating on shares of CytomX Therapeutics in a report on Thursday, February 2nd. Finally, Cann reiterated a “hold” rating on shares of CytomX Therapeutics in a report on Thursday, March 30th.
In other CytomX Therapeutics news, insider Sean A. Mccarthy sold 14,343 shares of the firm’s stock in a transaction on Monday, March 20th. The shares were sold at an average price of $19.60, for a total value of $281,122.80. Following the sale, the insider now directly owns 16,322 shares in the company, valued at approximately $319,911.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Robert C. Goeltz II sold 21,517 shares of the firm’s stock in a transaction on Monday, March 20th. The stock was sold at an average price of $19.81, for a total transaction of $426,251.77. Following the completion of the sale, the chief financial officer now owns 31,306 shares in the company, valued at $620,171.86. The disclosure for this sale can be found here. Insiders sold a total of 1,738,122 shares of company stock worth $30,244,598 over the last 90 days. Company insiders own 4.70% of the company’s stock.
Several hedge funds have recently modified their holdings of CTMX. Harbourvest Partners LLC acquired a new position in CytomX Therapeutics during the fourth quarter valued at about $110,000. Wells Fargo & Company MN boosted its position in CytomX Therapeutics by 253.6% in the third quarter. Wells Fargo & Company MN now owns 7,808 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 5,600 shares during the last quarter. Highbridge Capital Management LLC acquired a new position in CytomX Therapeutics during the fourth quarter valued at about $158,000. Trexquant Investment LP acquired a new position in CytomX Therapeutics during the fourth quarter valued at about $186,000. Finally, Neuberger Berman Group LLC acquired a new position in CytomX Therapeutics during the third quarter valued at about $224,000. Institutional investors and hedge funds own 54.31% of the company’s stock.
Shares of CytomX Therapeutics (NASDAQ:CTMX) traded up 1.98% during mid-day trading on Friday, hitting $16.46. The stock had a trading volume of 238,368 shares. The firm’s market cap is $601.09 million. CytomX Therapeutics has a 52-week low of $9.10 and a 52-week high of $20.02. The firm has a 50 day moving average price of $16.16 and a 200 day moving average price of $12.99.
CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Thursday, March 2nd. The biotechnology company reported ($0.39) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.45) by $0.06. The firm earned $6.27 million during the quarter. CytomX Therapeutics had a negative net margin of 523.78% and a negative return on equity of 52.50%. Equities analysts predict that CytomX Therapeutics will post ($1.75) EPS for the current year.
About CytomX Therapeutics
CytomX Therapeutics, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets.
What are top analysts saying about CytomX Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CytomX Therapeutics Inc and related companies.